Viewing nowKrelors 5mg (Rosuvastatin Calcium)
Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
Huons Meditech Co., Ltd.

MFDS item code 201604100 · Approved 2016.06.30 · Insurance code 670401450
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
This medication is used as an adjunct when diet and exercise alone do not adequately control hyperlipidemic conditions such as primary hypercholesterolemia and mixed dyslipidemia. It is also effective as an adjunct to diet and other therapies for patients with homozygous familial hypercholesterolemia. This drug helps lower total cholesterol and LDL cholesterol levels, thereby delaying the progression of atherosclerosis. It is also used in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia to reduce blood cholesterol levels in conjunction with dietary therapy. It is employed as an adjunct to dietary therapy for patients with primary dysbetalipoproteinemia and reduces the risk of cardiovascular events such as strokes, myocardial infarctions, and revascularization in middle-aged patients with elevated high-sensitivity C-reactive protein levels. In summary, this medication is used for various hyperlipidemias and risk reduction of cardiovascular diseases.
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer based on LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this drug 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this drug is contraindicated in some of these patients.
Age 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on the administration of doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.
This medication should not be used in certain patients. For instance, it should not be administered to individuals who are allergic to this drug, have severely impaired liver function, have a muscle disease, are taking specific immunosuppressants, have severe renal impairment, are pregnant or breastfeeding, and fertile women who are not using appropriate contraception. Additionally, high-dose use is prohibited in patients at risk of muscle disease. Risk factors include moderate renal impairment, hypothyroidism, a family or personal history of muscle disorders, alcohol dependence, and combination with certain medications. This medication contains lactose and should not be given to patients with lactose intolerance or related genetic disorders. Patients with poor liver function or excessive alcohol consumption should undergo regular liver enzyme tests when using this drug, and patients with hypercholesterolemia due to hypothyroidism or nephrotic syndrome should treat the underlying conditions first. Should symptoms such as muscle pain, weakness, or cramps occur, notify a doctor immediately and verify muscle damage through blood tests. If symptoms are severe or blood test results are elevated, discontinuation of the medication may be necessary. In cases of acute severe illness, the use of this medication should be discontinued, as rare occurrences of muscle weakness or ocular muscle weakness may arise. Combining this drug with other medications could increase the risk of muscle disease, so combination with fibrate-class drugs should be avoided. This medication can affect liver and kidney functions; therefore, regular testing is necessary, and in Asian patients, drug concentration may be higher, necessitating dose adjustments. Common side effects include headaches, dizziness, dyspepsia, muscle pain, increases in liver enzyme levels, while serious side effects such as severe skin reactions or liver damage can occur rarely. Pregnant or breastfeeding women should not use this medication, and women who may become pregnant must use appropriate contraception. In cases of overdose, as there are no specific antidotes, treatment should be symptomatic, with tests for liver function and muscle enzymes as needed. Caution should be exercised as dizziness may occur while driving or operating machinery. The drug's blood concentration can vary depending on specific genotypes; hence, dose adjustments may be necessary based on patient condition. Immediate discontinuation and medical attention should be sought if severe skin reactions occur.
Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distention, syncope, generalized pain, fatigue
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius.
Yellow round film-coated tablet
30 tablets/bottle, 100 tablets/bottle, 30 tablets/PTP[(10 tablets/PTP×3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 5.2mg
Tablet · Prescription medication
Huons Meditech Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.